Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Abstract
Increased generation of reactive oxygen species (ROS) and an altered redox status have long been observed in cancer cells, and recent studies suggest that this biochemical property of cancer cells can be exploited for therapeutic benefits. Cancer cells in advanced stage tumours frequently exhibit multiple genetic alterations and high oxidative stress, suggesting that it might be possible to preferentially eliminate these cells by pharmacological ROS insults. However, the upregulation of antioxidant capacity in adaptation to intrinsic oxidative stress in cancer cells can confer drug resistance. Abrogation of such drug-resistant mechanisms by redox modulation could have significant therapeutic implications. We argue that modulating the unique redox regulatory mechanisms of cancer cells might be an effective strategy to eliminate these cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, available data suggest that MGF-driven restoration of redox homeostasis represents a central mechanistic axis of its antitumor activity, rather than merely a downstream branch of apoptosis (84,85).”
From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [84]
In the citing paper
“Activation of oncogenes, aberrant metabolism, mitochondrial dysfunction, and loss of the tumor suppressor p53 can all promote increased ROS accumulation in cancer cells 69.”
From Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes (2010) · cites this paper as [69]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379 · cited 1×
“It has been observed that a small subpopulation of primary cancer cells expressing stem-cell markers was resistant to certain chemotherapeutic agents and radiatio”
BackgroundSchafer, F. Q., & Buettner, G. R. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00480-4 · Cited by 4,587 · cited 1×
“A moderate increase in ROS can promote cell proliferation and differentiatio”
BackgroundFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488 · cited 1×
“By exploiting the genetic differences between normal cells and cancer cells, several molecular-targeted drugs, such as imatinib (Gleevec; Novartis) and trastuzumab (Herceptin; Genentech/Roche), show promising therapeutic activity and few toxic side effect”
BackgroundCancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429 · cited 1×
“Redox status in cancer stem cells Recurrence of cancer after chemotherapy or radiotherapy is initiated by a subpopulation of residual malignant cells that are highly resistant to treatment and which are believed to be cancer-initiating cells or cancer stem cell”
Background(2012) · Hepatogastroenterology · doi:10.5754/hge12469 · Cited by 3,178
Production of large amounts of hydrogen peroxide by human tumor cells.
Szatrowski, T. P., & Nathan, C. (1991) · PubMed · Cited by 3,007
Association of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555 · cited 1×
“Recent studies showed that normal haemopoietic stem cells and normal mammary epithelial stem cells maintained ROS at lower levels than their mature progeny to prevent cellular differentiation and maintain long-term self-renewa”
BackgroundBjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272 · cited 1×
“This is consistent with the high incidence of p53 mutation or loss of p53 function in over 50% of human cancer”
Background
Research works printed but not linked: 1
- Kim, G. J., Chandrasekaran, K. & Morgan, W. F. Mitochondrial dysfunction, persistently elevated levels of reactive oxygen species and radiation-induced genomic instability: a review. Mutagenesis 21, 361–367 (2006). · DOI · Paper page
Cited by
Ayala, A., Muñoz, M. F., & Argüelles, S. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/360438 · Cited by 6,349
Reactive oxygen species (ROS) as pleiotropic physiological signalling agents
Sies, H., & Jones, D. P. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0230-3 · Cited by 5,335
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
“In the absence of the redox maintenance pathway that is supported by these tumour suppressors, malignant cells might be selectively kille”
BackgroundReactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling
Ray, P. D., Huang, B.-W., & Tsuji, Y. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.01.008 · Cited by 4,373
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
Metadata
- Authors
- Trachootham, D., Alexandre, J., & Huang, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Huang, Peng
- Venue
- Nature Reviews Drug Discovery
- Published
- 2009-05-29
- Volume
- 8
- Issue
- 7
- Pages
- 579-591
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1972779889
- Cited by
- 5,452
- References
- 163
- Citations by year
- 2026: 322 · 2025: 332 · 2024: 340 · 2023: 372 · 2022: 421 · 2021: 462 · 2020: 444 · 2019: 454 · 2018: 393 · 2017: 404 · 2016: 341 · 2015: 289 · 2014: 282 · 2013: 204 · 2012: 158
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA085563, R01CA109041, CA109041, R01CA085563, R01CA100428, CA100428)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer and biochemical research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- reactive oxygen species, oxidative stress, redox modulation, cancer cells, drug resistance, antioxidant capacity, anticancer agents, genomic instability
- MeSH terms
- Adaptation, Physiological, Animals, Glutathione, Humans, Neoplasms, Oxidation-Reduction, Neoplastic Stem Cells, Reactive Oxygen Species, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.